Glaxo's HIV launches continue to shine; U.K. cost watchdog slaps conditions on BMS hep C treatment;

> New GlaxoSmithKline ($GSK) launches--including HIV drugs Tivicay and Triumeq--helped the company offset sliding sales of Advair/Seretide in Q2, it said. Video

> The U.K.'s cost watchdog has restricted use of Bristol-Myers Squibb ($BMY) hep C treatment Daklinza to patients with genotype 1 or 4 who have either had previous drug treatment or who can't receive interferon. Report

> Pfizer's ($PFE) new cancer fighter Ibrance now boasts 22% market share among patients with estrogen-receptor-positive, HER2-negative tumors--up from 10% last quarter, CEO Ian Read said Tuesday. More

> Marina Maher Communications has hired Matthew Anderson as EVP and CMO as its pharmaceutical business continues to expand. Report

And Finally... Fat cartoon characters may make children eat more, a new study says. More